Medindia
Medindia LOGIN REGISTER
Advertisement

Insmed to Present at BioPharm Asia 2008 Conference

Thursday, September 4, 2008 General News
Advertisement
RICHMOND, Va., Sept. 4 Insmed Inc.(Nasdaq: INSM) a developer of follow-on biologics and biopharmaceuticals,today announced that Geoffrey Allan, Ph.D., CEO of Insmed, will present at theBioPharm Asia 2008 Conference. Dr Allan will be discussing Insmed'sexperiences to date regarding the regulatory issues surrounding follow-onbiologics (FOB) in the U.S. His presentation will take place on TuesdaySeptember 9, 2008 at the Sheraton Towers Hotel in Singapore.
Advertisement

This year's BioPharm Asia conference program will focus on the emergingFOB industry and cover development, manufacturing and marketing of FOB.

About Insmed
Advertisement

Insmed Inc. is a biopharmaceutical company with unique protein processdevelopment and manufacturing experience and a proprietary protein platformaimed at niche markets with unmet medical needs. For more information, pleasevisit www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuantto provisions of Section 21E of the Securities Exchange Act of 1934. Investorsare cautioned that such statements in this release, including statementsrelating to planned clinical study design, regulatory and business strategies,strategic alternatives, plans and objectives of management and growthopportunities for existing or proposed products, constitute forward-lookingstatements which involve risks and uncertainties that could cause actualresults to differ materially from those anticipated by the forward-lookingstatements. The risks and uncertainties include, without limitation, risksthat strategic alternatives may never be consummated, product candidates mayfail in the clinic or may not be successfully marketed or manufactured, we maylack financial resources to complete development of product candidates, theFDA may interpret the results of studies differently than us, competingproducts may be more successful, demand for new pharmaceutical products maydecrease, the biopharmaceutical industry may experience negative markettrends, our entrance into the follow-on biologics market may be unsuccessful,our common stock could be delisted from The NASDAQ Capital Market and otherrisks and challenges detailed in the Company's filings with the U.S.Securities and Exchange Commission, including the Company's Annual Report onForm 10-K for the year ended December 31, 2007. Readers are cautioned not toplace undue reliance on any forward-looking statements which speak only as ofthe date of this release. The Company undertakes no obligation to publiclyrelease the results of any revisions to these forward-looking statements thatmay be made to reflect events or circumstances that occur after the date ofthis release or to reflect the occurrence of unanticipated events.

SOURCE Insmed Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close